| Abstrakt: |
Introduction:In February 2020, tafamidis became the first drug approved to treat adults with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. However, the real-world treatment patterns of tafamidis 61 mg in Germany, including adherence rates, are not well studied.Methods:A non-interventional, retrospective, observational cohort study of German IQVIATMlongitudinal prescription data. Patients were statutory insured and received ≥1 prescription of tafamidis 61 mg between March 01, 2020 and August 31, 2021. Baseline characteristics were assessed descriptively. Treatment adherence was analysed using the modified medical possession ratio (mMPR) and proportion of days covered (PDC).Results:989 patients received ≥1 tafamidis prescription, with a mean age of 77.8 years, 81.1% were male, and 22.9% were treated by a cardiologist (Table 1). Overall, there were 7,753 prescriptions for tafamidis 61 mg. Mean supply and follow-up duration (first to last prescription) were 9.1 months and 7.8 months, respectively. The most frequent prior and concomitant medications were loop diuretics (73.7% and 69.7%), beta blockers (67.5% and 57.0%), direct factor Xa inhibitors (54.7% and 53.3%), and statins (55.0% and 47.4%). 879 patients received ≥2 prescriptions. Among these, mean mMPR was 1.03 (93.4% had an adherence rate ≥80%) and PDC was 0.90 (87.1% had adherence rate ≥80%; Figure 1).Conclusions:Patients prescribed tafamidis 61 mg in Germany display very high adherence. Based on professional society recommendations and using real world data, we found opportunities for concomitant medication optimization in patients with ATTR-CM and treated with tafamidis. |
